$4.20
At close: May 16, 4:03 PM EDT
$4.20
0.000.00%
Pre-Market: May 16, 4:03 PM EDT
Comments
Loading...
Veradigm Stock Guidance | OTC:MDRX | Benzinga
Veradigm issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 05/28/2024 | MDRX | Veradigm | FY | 2024 | — | — | — | $620.00M | $635.00M | — | Get Alert |
| 01/10/2024 | MDRX | Veradigm | FY | 2023 | $0.79 | $0.88 | $0.89 | $608.00M | $622.00M | $637.67M | Get Alert |
| 09/18/2023 | MDRX | Veradigm | FY | 2023 | $0.80 | $0.90 | $0.87 | $615.00M | $635.00M | $638.08M | Get Alert |
| 03/22/2023 | MDRX | Veradigm | FY | 2023 | $0.80 | $0.90 | $0.90 | $615.00M | $635.00M | $649.05M | Get Alert |
| 01/11/2023 | MDRX | Veradigm | FY | 2023 | $0.90 | $1.00 | $0.95 | $640.00M | $660.00M | $656.84M | Get Alert |
| 05/05/2022 | MDRX | Veradigm | FY | 2022 | — | — | — | $1.52B | $1.53B | $1.53B | Get Alert |
| 02/24/2022 | MDRX | Veradigm | FY | 2022 | — | — | — | $1.52B | $1.53B | $1.53B | Get Alert |
| 01/24/2022 | MDRX | Veradigm | Q4 | 2021 | — | — | — | $390.00M | $395.00M | $386.75M | Get Alert |
| 11/04/2021 | MDRX | Allscripts Healthcare | FY | 2021 | — | — | — | $1.50B | $1.50B | $1.50B | Get Alert |
| 08/05/2021 | MDRX | Allscripts Healthcare | FY | 2021 | — | — | — | $1.50B | $1.50B | $1.50B | Get Alert |
| 04/29/2021 | MDRX | Allscripts Healthcare | FY | 2021 | — | — | — | $1.50B | $1.50B | $1.50B | Get Alert |
| 02/25/2021 | MDRX | Allscripts Healthcare | FY | 2021 | — | — | — | $1.50B | $1.50B | $1.56B | Get Alert |
FAQ
What is the most recent guidance for Veradigm (MDRX)?
The most recent guidance for Veradigm (MDRX) was reported on January 10, 2024 for the full year 2023. The company provided earnings per share guidance in the range of $0.79 to $0.88, compared to the estimated EPS of $0.89. Additionally, Veradigm forecasted revenue between $0.61B and $0.62B for the quarter.
Browse guidance and forecast on all stocks.
